User menu

Management of hepatic metastasis from colorectal cancers: an update.

Bibliographic reference Sharma, Sharad ; Camci, Cemalettin ; Jabbour, Nicolas. Management of hepatic metastasis from colorectal cancers: an update.. In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 15, no.6, p. 570-580 (2008)
Permanent URL
  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
  2. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989;210:127–138.
  3. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003;12:165–192, xi.
  4. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110:13–29.
  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for meta-static colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318; discussion 318–21.
  6. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986;100:278–284.
  7. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–825; discussion 825–17.
  8. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703–710; discussion 710–1.
  9. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56:139–156.
  10. Ravikumar T.S., Steele Glenn D., Hepatic Cryosurgery, 10.1016/s0039-6109(16)44798-5
  11. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991;9:1105–1112.
  12. Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg 1987;205:264–270.
  13. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987;11:541–547.
  14. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575–4580.
  15. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–766.
  16. Kokudo N, Imamura H, Sugawara Y, Sakamoto Y, Yamamoto J, Seki M, Makuuchi M. Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg 2004;11:84–91.
  17. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003;90:567–574.
  18. Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004;78:238–244.
  19. Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239:722–730; discussion 730–2.
  20. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675–680; discussion 680–1.
  21. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997;173:467–471.
  22. Sitzmann JV, Greene PS. Perioperative predictors of morbidity following hepatic resection for neoplasm. A multivariate analysis of a single surgeon experience with 105 patients. Ann Surg 1994;219:13–17.
  23. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38–46.
  24. Mentha G, Huber O, Robert J, Klopfenstein C, Egeli R, Rohner A. Elective hepatic resection in the elderly. Br J Surg 1992;79:557–559.
  25. Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 92:2005;1165–1168.
  26. Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of potentially operable hepatic colorectal metastases is not useless but dangerous. BMJ 2004;329:1045–106.
  27. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis — meta-analysis. Radiology 2005;237:123–131.
  28. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748–756.
  29. Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003;227:752–757.
  30. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium-and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003;228:719–726.
  31. del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 2002;225:766–772.
  32. Ward J, Guthrie JA, Wilson D, Arnold P, Lodge JP, Toogood GJ, et al. Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging — comparison of optimized sequences. Radiology 2003;228:709–718.
  33. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluorine-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658–2670.
  34. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000;21:793–798.
  35. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027–1034; discussion 1035–6.
  36. Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR. Prospective evaluation of the impact of [18F] fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005;92:362–369.
  37. Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472–478.
  38. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255–3260.
  39. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428–432.
  40. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715–722, discussion 722–4.
  41. Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K. Resection of colorectal liver metastases. What prognostic factors determine patient selection?. Chirurg 2001;72:547–560.
  42. Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002;137:833–840.
  43. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181:153–159.
  44. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006;10:86–94.
  45. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 2002;236:397–406; discussion 406–
  46. Jarnagin WR, Conlon K, Bodniewicz J, Dougherty E, DeMatteo RP, Blumgart LH, Fong Y. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001;91:1121–1128.
  47. Figueras J, Valls C. The use of laparoscopic ultrasonography in the preoperative study of patients with colorectal liver metastases. Ann Surg 2000;232:721–723.
  48. Rifkin MD, Rosato FE, Branch HM, Foster J, Yang SL, Barbot DJ, Marks GJ. Intraoperative ultrasound of the liver. An important adjunctive tool for decision making in the operating room. Ann Surg 1987;205:466–472.
  49. Solomon MJ, Stephen MS, Gallinger S, White GH. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg 1994;168:307–310.
  50. Gozzetti G, Mazziotti A, Bolondi L, Cavallari A, Grigioni W, Casanova P, et al. Intraoperative ultrasonography in surgery for liver tumors. Surgery 1986;99:523–530.
  51. Staren ED, Gambla M, Deziel DJ, Velasco J, Saclarides TJ, Millikan K, Doolas A. Intraoperative ultrasound in the management of liver neoplasms. Am Surg 1997;63:591–596; discussion 596–7.
  52. Luck AJ, Maddern GJ. Intraoperative abdominal ultrasonography. Br J Surg 1999;86:5–16.
  53. Zacherl J, Scheuba C, Imhof M, Zacherl M, Langle F, Pokieser P, et al. Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg 2002;26:550–554.
  54. Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988;31:1–4.
  55. Adson Martin A., Resection of Hepatic Metastases From Colorectal Cancer, 10.1001/archsurg.1984.01390180015003
  56. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938–946.
  57. Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274–280.
  58. Ferrero A, Polastri R, Muratore A, Zorzi D, Capussotti L. Extensive resections for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2004;11:92–96.
  59. Inoue M, Kotake Y, Nakagawa K, Fujiwara K, Fukuhara K, Yasumitsu T. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000;70:380–383.
  60. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992;53:780–785; discussion 785–6.
  61. Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest 2001;119:1069–1072.
  62. Mansel JK, Zinsmeister AR, Pairolero PC, Jett JR. Pulmonary resection of metastatic colorectal adenocarcinoma. A 10 year experience. Chest 1986;89:109–112.
  63. Jaeck D, Bachellier P, Weber JC, Mourad M, Walf P, Boudjema K. Surgical treatment of synchronous hepatic metastases of colorectal cancers. Simultaneous or delayed resection? Ann Chir 1996;50:507–512; discussion 513–6.
  64. Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol 2000;30:7–11.
  65. Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233–241; discussion 241–2.
  66. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001;78:17–21.
  67. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004;47:1310–1316.
  68. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490–8499.
  69. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003;238:871–883; discussion 883–4.
  70. Harmon JW, Tang DG, Gordon TA, Bowman HM, Choti MA, Kaufman HS, et al. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann Surg 1999;230:404–411; discussion 411–3.
  71. Di Stefano DR, de Baere T, Denys A, Hakime A, Gorin G, Gillet M, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005;234:625–630.
  72. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127:512–519.
  73. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001;34:267–272.
  74. Fujii Y, Shimada H, Endo I, Kamiyama M, Kamimukai N, Tanaka K, et al. Changes in clinicopathological findings after portal vein embolization. Hepatogastroenterology 2000;47:1560–1563.
  75. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777–785.
  76. Oussoultzoglou E, Bachellier P, Rosso E, Scurtu R, Lucescu I, Greget M, Jaeck D. Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate. Ann Surg 2006;244:71–79.
  77. Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg 2002;137:94–99.
  78. Yamanaka N, Okamoto E, Fujihara S, Kato T, Fujimoto J, Oriyama T, et al. Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection? Cancer 1992;70:2263–2267.
  79. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004;240:1037–1049; discussion 1049–51.
  80. Kianmanesh R, Farges O, Abdalla EK, Sauvanet A, Ruszniewski P, Belghiti J. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003;197:164–170.
  81. Tanaka K, Shimada H, Matsuo K, Ueda M, Endo I, Togo S. Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 2007;33:329–335.
  82. Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D, et al. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology 2005;52:913–919.
  83. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg 2007;11:1498–1504; discussion 1504–5.
  84. Saiura A, Yamamoto J, Koga R, Kokudo N, Seki M, Oya M, et al. Outcome after hepatic resection of solitary liver metastasis from colorectal cancer in the caudate lobe. World J Surg 2007;32:2378–2383.
  85. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–1262.
  86. Cady B, Jenkins RL, Steele GD Jr, Lewis WD, Stone MD, McDermott WV, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998;227:566–571.
  87. Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg 1998;22:268–276; discussion 276–7.
  88. Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, et al. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg 1997;84:1077–1080.
  89. Yan TD, Padang R, Xia H, Zhao J, Li J, Morris DL. Management of involved or close resection margins in 120 patients with colorectal liver metastases: edge cryotherapy can achieve long-term survival. Am J Surg 2006;191:735–742.
  90. Gruenberger T, Jourdan JL, Zhao J, King J, Morris DL. Reduction in recurrence risk for involved or inadequate margins with edge cryotherapy after liver resection for colorectal metastases. Arch Surg 2001;136:1154–157.
  91. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243–9249.
  92. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–939.
  93. Zelek L, Bugat R, Cherqui D, Ganem G, Valleur P, Guimbaud R, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 2003;14:1537–1542.
  94. Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, et al. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 2006;17:1249–1254.
  95. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–1061; discussion 1061–4.
  96. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–115; discussion 116–7.
  97. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — a GERCOR study. J Clin Oncol 2006;24:394–400.
  98. Ho WM, Ma B, Mok T, Yeo W, Lai P, Lim R, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 2005;22:303–312.
  99. Seium Y, Stupp R, Ruhstaller T, Gervaz P, Mentha G, Philippe M, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol 2005;16:762–766.
  100. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005;23:7125–7134.
  101. Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007;25:4593–4602.
  102. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761–2767.
  103. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
  104. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003;7:1082–1088.
  105. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–1319.
  106. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1–7.
  107. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007;96:1037–1042.
  108. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006;24:4954–4955.
  109. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034–1044.
  110. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–466.
  111. Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004;22:3202–3204.
  112. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–2072.
  113. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–2474.
  114. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
  115. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845–853.
  116. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292–298.
  117. Nordlinger B, Van Cutsem E, Rougier P, Kohne CH, Ychou M, Sobrero A, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43:2037–2045.
  118. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–3945.
  119. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist 2007;12:825–839.
  120. Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V, Ducreux M. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86:4–9.
  121. Mitry E. Adjuvant chemotherapy in colon cancer. Gastroenterol Clin Biol 2006;30:94–95.
  122. Hohenberger P, Schlag P, Schwarz V, Herfarth C. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol 1990;44:245–251.
  123. Nordlinger B, Quilichini MA, Parc R, Hannoun L, Delva E, Huguet C. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 1987;205:256–563.
  124. Iwatsuki S, Esquivel CO, Gordon RD, Starzl TE. Liver resection for metastatic colorectal cancer. Surgery 1986;100:804–810.
  125. O'CONNELL MICHAEL J., ADSON MARTIN A., SCHUTT ALLAN J., RUBIN JOSEPH, MOERTEL CHARLES G., ILSTRUP DUANE M., Clinical Trial of Adjuvant Chemotherapy After Surgical Resection of Colorectal Cancer Metastatic to the Liver, 10.1016/s0025-6196(12)60567-9
  126. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976–4982.
  127. Parks R, Gonen M, Kemeny N, Jarnagin W, D’Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007;204:753–761; discussion 761–3.
  128. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784–3792.
  129. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888–4896.
  130. Kemeny N, Eid A, Stockman J, Gonen M, Schwartz L, Tetzlaff E, Paty P. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 2005;91:97–101.
  131. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20:1161–79; discussion 1179–80, 1185–6.
  132. Sibille A, Prat F, Chapelon JY, Abou el Fadil F, Henry L, Theillere Y, et al. Extracorporeal ablation of liver tissue by high-intensity focused ultrasound. Oncology 1993;50:375–379.
  133. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003;229:457–464.
  134. Curley SA, Izzo F. Radiofrequency ablation of hepatocellular carcinoma. Minerva Chir 2002;57:165–176.
  135. Curley SA, Davidson BS, Fleming RY, Izzo F, Stephens LC, Tinkey P, Cromeens D. Laparoscopically guided bipolar radiofrequency ablation of areas of porcine liver. Surg Endosc 1997;11:729–733.
  136. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003;10:52–58.
  137. Wood Thomas F., Rose D. Michael, Chung Mathew, Allegra David P., Foshag Leland J., Bilchik Anton J., Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications, 10.1007/bf02725339
  138. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001;6:24–33.
  139. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999;230:1–8.
  140. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158–171.
  141. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 2004;23:165–182.
  142. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003;10:1059–1069.
  143. Mann CD, Metcalfe MS, Neal CP, Rees Y, Dennison AR, Berry DP. Role of ultrasonography in the detection of resectable recurrence after hepatectomy for colorectal liver metastases. Br J Surg 2007;94:1403–1407.
  144. Suzuki Shohachi, Sakaguchi Takanori, Yokoi Yoshihiro, Kurachi Kiyotaka, Okamoto Kazuya, Okumura Takuya, Tsuchiya Yasuo, Nakamura Toshio, Konno Hiroyuki, Baba Satoshi, Nakamura Satoshi, Impact of repeat hepatectomy on recurrent colorectal liver metastases, 10.1067/msy.2001.112486
  145. Yamaguchi J, Komuta K, Matsuzaki S, Okudaira S, Fujioka H, Kanematsu T. Mode of infiltrative growth of colorectal liver metastases is a useful predictor of recurrence after hepatic resection. World J Surg 2002;26:1122–1125.
  146. Sasaki A, Aramaki M, Kawano K, Yasuda K, Inomata M, Kitano S. Prognostic significance of intrahepatic lymphatic invasion in patients with hepatic resection due to metastases from colorectal carcinoma. Cancer 2002;95:105–111.
  147. Ohlsson B, Tranberg KG, Lundstedt C, Ekberg H, Hederstrom E. Detection of hepatic metastases in colorectal cancer: a prospective study of laboratory and imaging methods. Eur J Surg 1993;159:275–281.
  148. Carter R, Hemingway D, Cooke TG, Pickard R, Poon FW, McKillop JA, McArdle CS. A prospective study of six methods for detection of hepatic colorectal metastases. Ann R Coll Surg Engl 1996;78:27–30.
  149. Metcalfe M, Mann C, Mullin E, Maddern G. Detecting curable disease following hepatectomy for colorectal metastases. ANZ J Surg 2005;75:524–527.
  150. Crowe PJ, Yang JL, Berney CR, Erskine C, Ham JM, Fisher R, Russell PJ. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 2001;25:996–1001.
  151. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293–299.
  152. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999;86:332–337.
  153. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 2005;140:183–189.